Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2009
The purpose of the study is to investigate the safety and the antiviral activity of two doses of LB80380 for 48 weeks in treatment-naive patients with chronic hepatitis B infection compared to entecavir 0.5 mg.
Epistemonikos ID: 107d824d8e0cf53c996ae1b2590fbda3d5f64592
First added on: Nov 24, 2021